铁了吗？IVM？

贵圈

贵圈

政府都对党
注册
2014-10-21
消息
32,808
荣誉分数
6,137
声望点数
373
双盲随机对照金标准
ivm，明确有效。

The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial​

Open AccessPublished:July 07, 2022DOI:Redirecting


PlumX Metrics
Previous ArticleU-shaped association between abnormal serum uric acid …

Next ArticleCOVID-19 serum can be cross-reactive and neutralizing …


Highlights​

  • •
    Drug-repurposing is a desirable approach to combat a new pathogen.
  • •
    The value of ivermectin as an anti-SARS-CoV-2 agent is debatable.
  • •
    Our study shows ivermectin treatment decreased viral-load and culture viability.
  • •
    These may reflect an anti-SARS-CoV-2 activity of ivermectin.
  • •
    Further studies are needed to explore its role in combating COVID.

Abstract​

Objectives​

Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin has anti-SARS-CoV-2 activity.

Methods​

The double-blinded trial compared patients receiving ivermectin for three days vs. placebo in non-hospitalized adult COVID-19 patients. RT-PCR from a nasopharyngeal-swab was obtained at recruitment and then every two days for at least 6 days. Primary endpoint was reduction of viral-load on the sixth-day as reflected by Ct level>30 (non-infectious level). The primary outcome was supported by determination of viral-culture viability.

Results​

Out of 867 patients screened, ultimately 89 were per-protocol evaluable (47 ivermectin and 42 placebo). On day 6, OR was 2.62 (95% CI: 1.09-6.31) in ivermectin arm reaching the endpoint. In a multivariable logistic regression model, the odds of a negative-test at day six was 2.28 time higher in the ivermectin group but reach significance only on day 8 (OR 3.70; 95% CI: 1.19-11.49, p=0.02). Culture-viability at days two to six were positive in 13.0% (3/23) of ivermectin samples vs. 48.2% (14/29) in the placebo group (p=0.008).

Conclusions​

There were lower viral-loads and less viable-cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity. It could lead to reduce transmission in these patients and encourage further studies with this drug.

铁了吗？
 
20220720_142112.jpg
 
说ivm没有金标准证据的。来看看。
 
贵圈 说:
双盲随机对照金标准
ivm，明确有效。

The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial​

Open AccessPublished:July 07, 2022DOI:Redirecting


PlumX Metrics
Previous ArticleU-shaped association between abnormal serum uric acid …

Next ArticleCOVID-19 serum can be cross-reactive and neutralizing …


Highlights​

  • •
    Drug-repurposing is a desirable approach to combat a new pathogen.
  • •
    The value of ivermectin as an anti-SARS-CoV-2 agent is debatable.
  • •
    Our study shows ivermectin treatment decreased viral-load and culture viability.
  • •
    These may reflect an anti-SARS-CoV-2 activity of ivermectin.
  • •
    Further studies are needed to explore its role in combating COVID.

Abstract​

Objectives​

Ivermectin, an anti-parasitic agent, also has anti-viral properties. Our aim was to assess whether ivermectin has anti-SARS-CoV-2 activity.

Methods​

The double-blinded trial compared patients receiving ivermectin for three days vs. placebo in non-hospitalized adult COVID-19 patients. RT-PCR from a nasopharyngeal-swab was obtained at recruitment and then every two days for at least 6 days. Primary endpoint was reduction of viral-load on the sixth-day as reflected by Ct level>30 (non-infectious level). The primary outcome was supported by determination of viral-culture viability.

Results​

Out of 867 patients screened, ultimately 89 were per-protocol evaluable (47 ivermectin and 42 placebo). On day 6, OR was 2.62 (95% CI: 1.09-6.31) in ivermectin arm reaching the endpoint. In a multivariable logistic regression model, the odds of a negative-test at day six was 2.28 time higher in the ivermectin group but reach significance only on day 8 (OR 3.70; 95% CI: 1.19-11.49, p=0.02). Culture-viability at days two to six were positive in 13.0% (3/23) of ivermectin samples vs. 48.2% (14/29) in the placebo group (p=0.008).

Conclusions​

There were lower viral-loads and less viable-cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity. It could lead to reduce transmission in these patients and encourage further studies with this drug.

铁了吗？
点击展开...

Open access并没有走完peer review的过程
 
辉瑞三期，走吗？
 

journal pre-proofs​

Journal pre-proofs are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication.
 
嗨呀，这药世卫组织的药物毒副作用数据库里，有大量使用的记录，而安全上问题极少。比起疫苗，比起PAX，比起人民希望，简直就是天真无邪。

为啥被禁？到现在加拿大还买不到。
 
小实验，加一起不到一百人，47 vs 42， 作者自己都说统计power不够。。。

巴西一千多人的RCT（600 vs 600）都不能证明管用。。。

现在事实已经证明了，啥药不吃都能对抗新型covid Omicron。

疫苗都打了好几针了，还有人在纠结IVM了。。。？

主题“Ivermectin doesn’t treat COVID or keep people out of hospital, study finds”的帖子 https://bbs.comefromchina.com/threads/1766011/post-12351099
 
哈哈哈，记得pax报告有多少人吗？
没完没了的各种理由。
 
是啊，IVM国家就是好，看着疫苗国家，一浪又一浪。惨不忍睹。
 
要不说傻逼呢，
同样的句式
“”打11针疫苗，也挡不住omicron 怎么还有人纠结打不打疫苗呢？“”
 
IVM减少毒量。大有益处。现在证明了。
 
啥疫苗也不用打，很多国家死亡数少得多。
 
还纠结，因为人类还有希望，不全是哈巴狗。
 
您必须登录或注册才可回复。

相关推荐

metropolis
WHO更新治疗指南：对伊维菌素，羟氯喹等COVID-19 抗病毒药物
2
回复
26
查看
2K
贵圈
贵圈
metropolis
美国B2轰炸机袭击伊朗支持的也门胡塞武装
回复
0
查看
782
metropolis
metropolis
metropolis
CNN 文件显示，冠状病毒的基因序列在中国正式披露前两周已提交给美国数据库
2 3 4
回复
46
查看
5K
metropolis
metropolis
C
都一年多现在才注意到渥太华河边的Sir John A. Macdonald Parkway有了新名字 Kichi Zibi Mikan
    • 喜欢
2
回复
20
查看
913
jy
J
Jay Wang
大选结束了，阿蹄儿重新回到头版！
回复
5
查看
606
ccc
ccc
后退
顶部